Skip to main content

porustobart

Generic: Porustobart

porustobart: 2 clinical trials tracked.

porustobart evidence translation

What we can confirm

2 tracked trials

No verified listed company relationship

What it means

AI will separate confirmed drug evidence from unknown company context.

What to watch

Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected

Prepared research question

What is verified about porustobart, and what remains unknown?

Run cited research

Traceable citations · Unknowns marked

See linked entities and source evidence3 indications · 0 study sponsors

Study sponsors

No additional listed-company sponsor is linked.

Clinical Trial Registry Records (2)

A Phase 2, Open-Label, Multicenter, Randomized Trial Evaluating the Efficacy and Safety of Different Schedules of Neoadjuvant Pembrolizumab and Porustobart in Patients With Resectable pMMR/MSS Colon Cancer

NCT07808151Registry updated 2026-09-08·Phase 2
Not yet recruiting

Primary endpoint: Major Pathologic Response (MPR) rate by Blinded Independent Pathologic Review (BIPR)

InterventionalRandomizedopen100 targetStarted 2026-09Completion 2029-0930 sites · Belgium, Italy, Netherlands, Spain…Solstice Oncology, Inc.

An Open-Label, Phase 1 Clinical Study to Evaluate the Safety, Tolerability, PK/PD and Preliminary Efficacy of HBM4003 in Combination With Toripalimab/ Tislelizumab in Patients With Advanced NEN and Other Solid Tumors

NCT05167071Registry updated 2025-04-27·Phase 1

Primary endpoint: Part 1: DLT

InterventionalRandomizedopen53 targetStarted 2021-12Completion 2026-061 site · ChinaHarbour BioMed (Guangzhou) Co. Ltd.